Modulation of the renin-angiotensin system against COVID-19: A path forward?

Modulation of the renin-angiotensin system against COVID-19: A path forward?

Soon after the pandemic outbreak in 2020, it was proposed that binding of SARS-CoV-2 to the angiotensin converting enzyme-2 may explain most of COVID-19’s manifestations. Therefore, manipulation of the renin-angiotensin system (RAS) by using well known and commercialized blockers of its classical ar...

Full description

Saved in:

Bibliographic Details
Main Authors:	Serge Camelo, Waly Dioh, J. Pedro Teixeira, Laurence W. Busse, Girish Nair, Gaëtan Plantefeve, Capucine Morelot-Panzini, Suzana Margareth Lobo, Wesley H. Self, Sean P. Collins, Rob Van Maanen, Stanislas Veillet
Format:	Article
Language:	English
Published:	Elsevier 2025-05-01
Series:	International Journal of Infectious Diseases
Subjects:	COVID-19 Renin-angiotensin system Angiotensin type 1 receptor Angiotensin-II Angiotensin-(1-7) Mas receptor
Online Access:	http://www.sciencedirect.com/science/article/pii/S1201971225000906
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

LONG-TERM EFFECTS OF OLMESARTAN, AN ANG II RECEPTOR ANTAGONIST, ON BLOOD PRESSURE AND THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSIVE PATIENTS
by: Shuichi Ichikawa, et al.
Published: (2011-06-01)

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension
by: Juan Meng, et al.
Published: (2020-01-01)

The role of the classical renin–angiotensin system and angiotensin-converting enzyme 2/Ang(1–7)/Mas axis in pulmonary fibrosis
by: Changhui Lang, et al.
Published: (2025-07-01)

Renin–angiotensin system inhibition in COVID-19 patients: Friend or foe?
by: Bilgehan Karadağ
Published: (2020-07-01)

RENIN-ANGIOTENSIN SYSTEM IN REGULATION OF HEMATOPOIESIS
by: M. L. Kanaeva, et al.
Published: (2018-02-01)

ANGIOTENSIN II RECEPTOR TYPE 1 EXPRESSION IN PATIENTS WITH MULTIFOCAL ATHEROSCLEROSIS
by: I. S. Mykhailichenko
Published: (2016-04-01)

Angiotensins and rheumatoid arthritis
by: N. M. Savushkina, et al.
Published: (2019-01-01)

The role of renin-angiotensin system and angiotensin-converting enzyme 2 (ACE2) in the development and course of viral infection COVID-19 in patients with diabetes mellitus
by: O. K. Vikulova, et al.
Published: (2020-08-01)

Effect of renin-angiotensin -aldosterone system blockers on myocardial remodeling processes and risk for atrial fibrillation in patients with arterial hypertension
by: O. M. Drapkina, et al.
Published: (2014-07-01)

Left ventricular hypertrophy: renin4angiotensin system role
by: F. T. Ageev, et al.
Published: (2008-04-01)

Angiotensin II type 1 receptor antagonists and ACE inhibitors in the regulation of hemodynamics and renin-angiotensin-aldosterone system activity: focus on the organ protection
by: M. L. Maksimov, et al.
Published: (2010-04-01)

EFFECTS OF VITAMIN D ON THE RENIN-ANGIOTENSIN SYSTEM
by: L. Pashova-Stoyanova, et al.
Published: (2019-09-01)

INACTIVATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM. WHICH CLASS OF ANTIHYPERTENSIVE MEDICINE PRODUCTS TO PREFER?
by: S. V. Stolov
Published: (2020-12-01)

Comparison of angiotensin converting enzyme 1 levels to the grading of knee osteoarthritis
by: Fidelia Elvira Da Costa Rao, et al.
Published: (2024-06-01)

TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS
by: L. N. Malay, et al.
Published: (2016-01-01)

The systemic angiotensin-II role in the development of retinopathy of prematurity
by: N. A. Osipova, et al.
Published: (2023-07-01)

Duration of rheumatoid arthritis changes blood levels of angiotensin and aldosterone
by: Boris A. Rebrov, et al.
Published: (2023-12-01)

Angiotensin receptor‐neprilysin inhibitor adherence and outcomes in heart failure with reduced ejection fraction
by: Dong‐Hyuk Cho, et al.
Published: (2025-02-01)

Renin-angiotensin and kallikrein-kinin systems in diabetic renal damage
by: Igić Rajko
Published: (2019-01-01)

Association between renin-angiotensin system gene polymorphism and cardio-ankle vascular index in patients with COVID-19
by: V. I. Podzolkov, et al.
Published: (2024-12-01)

Myocardial and Renal Renin–Angiotensin System Enzyme Activity in Dogs
by: Emma C. Weitzhandler, et al.
Published: (2025-07-01)

ACE INHIBITORS AND ANGIOTENSIN II RECEPTOR BLOCKERS IN THE TREATMENT OF CARDIOVASCULAR DISEASE: WHAT TO CHOOSE?
by: K. A. Ghyamdzhyan, et al.
Published: (2012-09-01)

Renin-angiotensin system as an emerging target to modulate adult neurogenesis in health and disease
by: Jannette Rodríguez-Pallares, et al.
Published: (2025-07-01)

Impaired aldosterone response to potassium and hyperkalemia in patients receiving a renin-angiotensin-aldosterone system inhibitor
by: Miyeon Kim, et al.
Published: (2025-05-01)

The Renin–Angiotensin System Modulates SARS-CoV-2 Entry via ACE2 Receptor
by: Sophia Gagliardi, et al.
Published: (2025-07-01)

Acquisition of renin-angiotensin-aldosterone system inhibitors for the treatment of cardiovascular diseases in regions of the Far Eastern Federal District
by: M. S. Soboleva, et al.
Published: (2020-04-01)

THE RENIN-ANGIOTENSIN SYSTEM AND ITS INVOLVEMENT IN PAIN CONTROL. A NEW INSIGHT INTO AN OLD SYSTEM
by: Daniela Pechlivanova, et al.
Published: (2025-04-01)

Novel Antihypertensive Medications to Target the Renin-Angiotensin System: Mechanisms and Research
by: Zhe Jiang, et al.
Published: (2025-04-01)

Effect of angiotensin-converting enzyme inhibitors versus that of angiotensin receptor blockers on survival in patients undergoing hemodialysis: a nationwide observational cohort study
by: Seok Hui Kang, et al.
Published: (2024-12-01)

IS IT WORTH TO DISCONTINUE DRUGS BLOCKING THE ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN THE PERI-OPERATIVE PERIOD?
by: V. V. Lomivorotov, et al.
Published: (2018-07-01)

ANGIOTENSIN RECEPTOR BLOCKERS WITH PLEIOTROPIC PROPERTIES: A NEW STANDARD IN CARDIOVASCULAR RISK MANAGEMENT AND TREATMENT OF HYPERTENSION
by: V. I. Podzolkov, et al.
Published: (2017-07-01)

RAA System and Exercise Relationship
by: Sadettin Ünsal, et al.
Published: (2019-09-01)

Is there a difference between an angiotensin-converting enzyme inhibitor and an angiotensin-specific receptor blocker for the treatment of hypertension?
by: James A. Ker
Published: (2015-05-01)

Efficacy of Combined Bevacizumab and Angiotensin-Converting Enzyme Inhibitors or Angiotensin II type 1 Receptor Blockers in Metastatic Colorectal Cancer Patients
by: Ali Kaan Güren, et al.
Published: (2025-04-01)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: IS THERE A REASON TO CONSIDER AN EQUIVALENCE OF TWO DRUG CLASSES FROM THE EVIDENCE BASED MEDICINE STANDPOINT
by: S. Yu. Martsevich
Published: (2015-09-01)

Angiotensin II and Cardiovascular Disease: Balancing Pathogenic and Protective Pathways
by: Ulvi Bayraktutan
Published: (2025-07-01)

Gating Mechanism for Biased Agonism at Angiotensin II Type 1 Receptors
by: Graham J. Moore, et al.
Published: (2025-05-01)

Efficacy of angiotensin receptor blockers for erectile dysfunction in hypertensive men: A systematic review
by: Swati Sucharita Dash, et al.
Published: (2024-01-01)

Blocking angiotensin earlier with RAS blockers, statins, and heparin in high-risk COVID-19 patients: Is the remedy here?
by: Imdat Eroğlu, et al.
Published: (2020-07-01)

Treatment of Patients with COVID-19 and Concomitant Cardiovascular Diseases: Do not Forget About the Principles of Evidence-based Medicine
by: S. Yu. Martsevich
Published: (2020-05-01)